S&P 500   2,659.41 (-0.16%)
DOW   22,679.99 (+7.73%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,679.99 (+7.73%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,679.99 (+7.73%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,679.99 (+7.73%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
Log in

NASDAQ:ITRMIterum Therapeutics Stock Price, Forecast & News

$2.67
+0.02 (+0.75 %)
(As of 04/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.59
Now: $2.67
$2.80
50-Day Range
$1.55
MA: $2.42
$3.15
52-Week Range
$1.40
Now: $2.67
$9.30
Volume21,900 shs
Average Volume85,603 shs
Market Capitalization$37.27 million
P/E RatioN/A
Dividend YieldN/A
Beta0.95
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.
Read More
Iterum Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.50 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ITRM
CUSIPN/A
Phone353-1903-8920

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40,000.00
Book Value($1.88) per share

Profitability

Net Income$-103,130,000.00

Miscellaneous

Employees48
Market Cap$37.27 million
Next Earnings Date5/12/2020 (Estimated)
OptionableNot Optionable

Receive ITRM News and Ratings via Email

Sign-up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter.


Iterum Therapeutics (NASDAQ:ITRM) Frequently Asked Questions

How has Iterum Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Iterum Therapeutics' stock was trading at $2.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ITRM shares have increased by 31.5% and is now trading at $2.67. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Iterum Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 2 sell ratings, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Iterum Therapeutics.

When is Iterum Therapeutics' next earnings date?

Iterum Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Iterum Therapeutics.

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics PLC (NASDAQ:ITRM) announced its quarterly earnings data on Thursday, March, 12th. The company reported ($1.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.70) by $0.11. View Iterum Therapeutics' earnings history.

What price target have analysts set for ITRM?

6 brokers have issued twelve-month price objectives for Iterum Therapeutics' shares. Their forecasts range from $4.00 to $17.00. On average, they expect Iterum Therapeutics' stock price to reach $10.33 in the next year. This suggests a possible upside of 287.0% from the stock's current price. View analysts' price targets for Iterum Therapeutics.

What are Wall Street analysts saying about Iterum Therapeutics stock?

Here are some recent quotes from research analysts about Iterum Therapeutics stock:
  • 1. According to Zacks Investment Research, "Iterum Therapeutics plc is a clinical-stage pharmaceutical company. It develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. The company's product pipeline consists of uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra abdominal infections. Iterum Therapeutics plc is based in Dublin, Ireland. " (11/19/2019)
  • 2. HC Wainwright analysts commented, "Valuation We employ a rNPV model, shown below, to value ITRM at $17 per share. We estimate the current risk- adjusted per-share value of sulopenem across its three indications: (1) $6.44 for cUTI (68% POS; $244M peak revenues in 2035); (2) $5.31 for uUTI (65% POS; $179M peak sales in 2035); and (3) $5.46 for cIAI (68% POS; $153M peak sales in 2035)." (6/21/2019)

Has Iterum Therapeutics been receiving favorable news coverage?

Media coverage about ITRM stock has trended very negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iterum Therapeutics earned a news impact score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutIterum Therapeutics.

Are investors shorting Iterum Therapeutics?

Iterum Therapeutics saw a decrease in short interest in March. As of March 13th, there was short interest totaling 437,200 shares, a decrease of 15.0% from the February 27th total of 514,300 shares. Based on an average daily trading volume, of 47,700 shares, the days-to-cover ratio is presently 9.2 days. Currently, 7.4% of the shares of the stock are short sold. View Iterum Therapeutics' Current Options Chain.

Who are some of Iterum Therapeutics' key competitors?

What other stocks do shareholders of Iterum Therapeutics own?

Who are Iterum Therapeutics' key executives?

Iterum Therapeutics' management team includes the following people:
  • Mr. Corey N. Fishman, Pres, CEO & Director (Age 54)
  • Ms. Judith M. Matthews, Chief Financial Officer (Age 49)
  • Dr. Michael W. Dunne, Chief Scientific Officer (Age 59)
  • Mr. Benjamin M. Pe, VP of Operations

When did Iterum Therapeutics IPO?

(ITRM) raised $80 million in an IPO on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Iterum Therapeutics' stock symbol?

Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM."

How do I buy shares of Iterum Therapeutics?

Shares of ITRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iterum Therapeutics' stock price today?

One share of ITRM stock can currently be purchased for approximately $2.67.

How big of a company is Iterum Therapeutics?

Iterum Therapeutics has a market capitalization of $37.27 million and generates $40,000.00 in revenue each year. The company earns $-103,130,000.00 in net income (profit) each year or ($7.10) on an earnings per share basis. Iterum Therapeutics employs 48 workers across the globe. View additional information about Iterum Therapeutics.

What is Iterum Therapeutics' official website?

The official website for Iterum Therapeutics is http://www.iterumtx.com/.

How can I contact Iterum Therapeutics?

Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The company can be reached via phone at 353-1903-8920 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel